Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review

Buprenorphine–naloxone “microdosing”: an alternative induction approach for the treatment of opioid use disorder in the wake of North America’s increasingly potent illicit drug market

(2020) Privia A. Randhawa et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Transition From Methadone to Buprenorphine Using a Short-acting Agonist Bridge in the Inpatient Setting

(2020) Jonathan Callan et al.   Journal of Addiction Medicine

Case Report: Buprenorphine Induction Using Transdermal Buprenorphine in a Veteran With Opioid Use Disorder and Psychosis, Managing Precipitated Withdrawal

(2020) Kathryn R Kinasz et al.   MILITARY MEDICINE

Initiating Opioid Agonist Treatment for Opioid Use Disorder in the Inpatient Setting

(2019) Amer Raheemullah et al.   JAMA Internal Medicine

Takotsubo cardiomyopathy associated with buprenorphine precipitated withdrawal

(2018) Ryan M. Surmaitis et al.   CLINICAL TOXICOLOGY

Transdermal Buprenorphine, Opioid Rotation to Sublingual Buprenorphine, and the Avoidance of Precipitated Withdrawal

(2015) Howard Kornfeld et al.   AMERICAN JOURNAL OF THERAPEUTICS

Sublingual Buprenorphine for Chronic Pain

(2013) Kristen Rosen et al.   CLINICAL JOURNAL OF PAIN

Buprenorphine Is a Weak Partial Agonist That Inhibits Opioid Receptor Desensitization

(2009) M. S. Virk et al.   JOURNAL OF NEUROSCIENCE

Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study

(2008) Michael Soyka et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY